Sanya Sukduang

Sanya Sukduang is a patent litigator with a practice focused on the life sciences sector. His work primarily involves representing brand-name pharmaceutical and biotechnology companies in complex patent disputes, including Hatch-Waxman litigation related to Abbreviated New Drug Applications (ANDAs), as well as matters concerning biologics and medical devices. He also counsels clients on pre-litigation strategy, due diligence, and patent portfolio management. As of February 2026, Sukduang is a partner at Norton Rose Fulbright.

The authoritative case data shows Sukduang as lead counsel for the defendant, Soleno Therapeutics, consistent with his focus on representing patent holders and brand manufacturers in the pharmaceutical industry. Prior to joining Norton Rose Fulbright, he was a partner at Cooley, which he joined in 2020. Before that, he practiced for over a decade at the intellectual property firm Finnegan, Henderson, Farabow, Garrett & Dunner.

Sukduang has significant experience litigating in federal district courts, before the Patent Trial and Appeal Board (PTAB), and in appeals to the U.S. Court of Appeals for the Federal Circuit. A notable outcome includes securing a key Federal Circuit victory for Liquidia Technologies that affirmed a PTAB decision invalidating a United Therapeutics patent, clearing a path for regulatory approval of Liquidia's drug. He is also an author on legal topics and has served as an adjunct professor at the American University Washington College of Law, where he also earned his J.D.